Condition: Esophageal and/or Cardia Cancer · Melanoma · Urothelial Carcinoma (UC) · Sponsor: Shanghai Henlius Biotech
This is a multicenter, randomized, double-blind, parallel-controlled phase I clinical study to evaluate the similarity in PK profile, efficacy, safety and immunogenicity of HLX18 and OPDIVO® in patients with resected esophageal or gastroesophageal junction cancer (EC/GEJC), melanoma (MEL), or urothelial carcinoma (UC).
This description comes directly from the study's public registry record.
Chang Chen · +86 138 1686 9003 · chenthoracic@163.com
Always discuss trial participation with your own doctor first.
| Fujian Medical University Union Hospital | Fuzhou, China | Recruiting |
| The First Affiliated Hospital Zhejiang University School Of Medicine | Hangzhou, China | Recruiting |
| The First Affiliated Hospital of Henan University of Science & Technology | Luoyang, China | Recruiting |
| The Second Hospital of Tianjin Medical University | Tianjin, China | Recruiting |
| The First Affiliated Hospital of Wenzhou Medical University | Wenzhou, China | Recruiting |
| Union Hospital, Tongji Medical College,Huazhong University of Science and Technology | Wuhan, China | Recruiting |
| The Second Affiliated Hospital of Xi'an Jiaotong University | Xi'an, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07518043